|
|
 |
|
Viewing report
|
|
|
|
Enabling Oncology Diagnostics: Predictive Biomarkers Based on Genes, Proteins, and Pathways
Decision Resources, Inc., Dec 2008, Pages: 33
Introduction
In efforts to find new ways to transform the drug development paradigm and the clinical management of cancer, scientists are increasingly turning to discovering cancer biomarkers and developing targeted therapies. The infusion of novel methods, technologies, and strategies—through exploring genes, proteins, and pathways – is enriching traditional approaches. Although notable challenges exist, the possibilities are
essentially endless: Where will targeted therapies and companion diagnostics in oncology take us?
Get the Answers You Need to Shape Your Strategy
- ER/PR, HER2, KRAS mutations, VEGF pathway, and EGFR expression, mutation, and amplification. An ever-increasing number of identified biomarkers exist for breast, colorectal, and lung cancers—which ones will lead us to the better targeted therapies and companion diagnostics?
- The monumental role of Dako’s HercepTest in the dramatic success of Roche/Genentech/Chugai’s Herceptin is undeniable and infamous in biopharma circles. How will other companion diagnostics and targeted therapies fare in comparison? Will Abbott’s recent alliance with Roche, OSI Pharmaceuticals, and Genentech to develop a diagnostic test for Tarceva in non-small-cell lung cancer be as successful?
- HER2 protein expression is commonly detected using technologies such as immunochemistry (IHC), fluorescence in situ hybridization (FISH), and chromogenic in situ hybridization (CISH). What is the role of emerging technologies, such as silver in situ hybridization (SISH), in the discovery and development of predictive biomarker-based diagnostic tests?
Scope
- Predictive biomarkers for the treatment of breast, colorectal, and lung cancers: Explores how genes, proteins, and pathways in oncology are being studied, incorporated in clinical trials, and used to improve treatment options for patients suffering from these cancers.
- Industry trends to improve therapeutics: A renewed interest in predictive biomarkers from both the diagnostics and drug industries is creating changes and increasing collaboration. Using biomarkers earlier in drug development, considering changes in business models, and participating in related consortia are some of the ways companies are advancing the notion of personalized medicine.
- Expert commentary: Decision Resources analyst Andrew Merron, Ph.D., examines the impact of predictive biomarkers on the drug market, with specific emphasis on the role of companion diagnostics as threats or opportunities for the NSCLC drug market.
- Outlook: Biomarker discovery and diagnostics development are at the core of novel products in the war on cancer. Examine ways stakeholders can ensure a streamlined approach to applying cancer biomarker development to targeted therapies and companion diagnostics.
Customers who bought this item also bought
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
What Is the Future Role of Predictive Safety Biomarkers in Drug Development?
Companion Biomarkers in Drug Development
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Biomarkers - Technologies, Markets and Companies
Cancer Biomarkers: Players, Products and Prospects (Volume I)
Expanding Applications of Personalized Medicine: Use of Biomarkers in Prognostic, Predictive and Pharmacogenetic Tests in a Targeted Approach
Trends in the Commercialization of Biomarkers: Tests and Companies
Cancer Biomarkers: New Tools for Transforming Cancer Management
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Biomarkers 2008
How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers
|
|
|
|
